Clinical trials: Amlodipine
Essential Hypertension
A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension
This randomized, double-blind, multicenter phase 3 clinical trial evaluated the efficacy and safety of KDF1901, a single-pill triple combination of valsartan, amlodipine, and chlorthalidone, in patients with essential…
- Trial name
- NCT07116863
- Testing
- KDF1901-R0, KDF1901-L, KDF1901
- Where
- 2 sites in South Korea
- Volunteers
- 286 people
- Sponsor
- Kyungdong Pharmaceutical Co., Ltd.
Hypertension
Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension
To evaluate the blood pressure lowering effect and safety of LCZ696 when given alone and in combination with amlodipine in patients with essential hypertension.
- Trial name
- NCT01865188
- Testing
- LCZ696, Amlodipine, LCZ696 and amlodipine combination
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day
This study was a multicenter, randomized, PROBE-type (prospective, randomized, open label, blinded end-point) study of 12 weeks duration comprising four visits, carried out in patients with essential arterial hypertension not…
- Trial name
- NCT00700271
- Testing
- Amlodipine, Valsartan
- Where
- 2 sites in France, Tunisia
- Volunteers
- 478 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
This CLAZ696B11302 study is composed of two parts; the Core part including double-blind period, and the open-label extension (OLE) part which is an open-label extension of the Core part.
- Trial name
- NCT06236061
- Testing
- LCZ, LCZ/AML 200 mg/2.5 mg, LCZ/AML 200 mg/5 mg
- Where
- 43 sites in Japan
- Volunteers
- 718 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension
A Randomized, Double-blind, Multicenter, Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypertension
- Trial name
- NCT04488978
- Testing
- Irbesartan/Amlodipine
- Where
- South Korea
- Volunteers
- 440 people
- Sponsor
- Handok Inc.
Hypertension
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients
This trial will compare valsartan and amlodipine combination therapies to valsartan and amlodipine monotherapy,and placebo for treating patients with hypertension
- Trial name
- NCT00409643
- Testing
- valsartan+amlodipine combination, valsartan, amlodipine
- Where
- 2 sites in United States, Germany
- Volunteers
- 1,259 people
- Sponsor
- Novartis
Hypertension
CKD-330 Drug-Drug Interaction Study (Amlodipine)
The purpose of this study is to evaluate a pharmacokinetic drug interaction and safety of Amlodipine between free combination of Amlodipine and Candesartan and Amlodipine monotherapy.
- Trial name
- CKD-330(A) (NCT02064556)
- Testing
- Amlodipine 10mg, Amlodipine 10mg/Candesartan 32mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy
The Efficacy of a Fixed Dose Combination of Telmisartan/S-Amlodipine on 24-hour Ambulatory BP Control Compared with Telmisartan Monotherapy
- Trial name
- TENUVA-BP (NCT02231788)
- Testing
- Telminuvo®Tab. 40/2.5mg, Telmitrend®Tab. 80mg
- Where
- 11 sites in South Korea
- Volunteers
- 217 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
To evaluate the efficacy of Amlodipine-Folic Acid Tablets on reduction of blood pressure and plasma total homocysteine.
- Trial name
- NCT01956786
- Testing
- Amlodipine-FA tablet,low dose group, Amlodipine-FA tablet,high dose group, Amlodipine
- Where
- 3 sites in China
- Volunteers
- 540 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd